OtoID: New extended frequency, portable audiometer for ototoxicity monitoring

VA RR&D National Center for Rehabilitative Auditory Research (NCRAR), 3710 SW US Veterans Hospital Rd, Portland, OR 97239. .
The Journal of Rehabilitation Research and Development (Impact Factor: 1.43). 11/2013; 50(7):997-1006. DOI: 10.1682/JRRD.2012.09.0176
Source: PubMed


Portability of equipment is an increasingly important component in the practice of audiology. We report on a new device, the OtoID, that supports evidence-based ototoxicity testing protocols, provides capability for hearing testing on the hospital treatment unit, and can automate patient self-testing. The purpose of this article is to report on the validation and verification of the OtoID portable audiometer in 40 subjects both young and old, with and without hearing impairment. Subjects were evaluated by an audiologist using the manual hearing test program and then self-tested via an automated testing program. Testing was done in a sound booth and on a hospital treatment unit. Therefore, data were collected in four conditions (booth vs hospital unit and automated vs manual testing) and analyzed for testing bias, repeatability, and American Speech-Language-Hearing Association-significant ototoxicity false-positive rate. Repeatable hearing threshold results were obtained on all subjects who performed the test, regardless of hearing status or testing location.

Download full-text


Available from: Marilyn F Dille,
  • Source
    • "This device, developed specifically for this task, enables veteran capability to test his/her hearing just before each chemotherapeutic treatment. While the device's effectiveness is well documented when compared to other HFAs (Jacobs et al, 2012), and on participants not undergoing chemotherapy but who vary in age and hearing ability (Dille et al, 2013), this is our first report of findings with cancer patients. The aim of this study was to establish the sensitivity and specificity of an abbreviated airconduction hearing test done by the OtoID in a sevenfrequency range, known to be most sensitive to early ototoxic hearing change, as a means to monitor hearing for change during cancer treatment. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Teleaudiology offers the opportunity of providing health services to remote locations and underserved populations who lack access to audiology personnel and clinical resources. Remote monitoring of hearing is especially important when considering side effects of chemotherapy drugs such as cisplatin, which has the potential to seriously damage a patient’s hearing. A person receiving cisplatin therapy would benefit significantly by having their high frequency hearing tested frequently during therapy; if hearing was found to be impacted, an oncologist and audiologist could be notified and a dosing change or alternative drug option could be considered to avoid long term and profound hearing loss. We have previously reported on the OtoID, which is a device that enables remote monitoring of hearing by a patient during chemotherapy treatment. In this paper, we present results showing how hearing screenings done using the OtoID generally match well when done by a patient compared with when an audiologist performs the test. We show that automated testing by 21 subjects undergoing chemotherapy treatment with cisplatin enabled subjects to use a self-test to detect ASHA-specific changes in hearing with a sensitivity of 80.6% and a specificity of 86.3%. Results suggest that the OtoID may be useful in the future for in-home identification of hearing changes while undergoing ototoxic chemotherapy treatment.
    Journal of the American Academy of Audiology 09/2015; DOI:10.3766/jaaa.15028 · 1.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prevention and rehabilitation of hearing loss and tinnitus, the two most commonly awarded service-connected disabilities, are high priority initiatives in the Department of Veterans Affairs (VA). At least 4,000 Veterans, most with significant hearing loss, will receive cisplatin this year, with more than half sustaining permanent hearing shift and nearly 40% developing new tinnitus. With improved survivability following cancer treatment, Veterans treated with cisplatin are approached with the dual goals of effective treatment and preserved quality of life. This article describes COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. The program includes an individualized pretreatment prediction model that identifies the likelihood of hearing shift given cisplatin dose and patient factors. It supports both manual and automated hearing testing with a newly developed portable audiometer capable of performing the recommended procedures on the chemotherapy unit during treatment. It also includes objective methods for identifying outer hair cell changes and predicting audiogram changes using distortion-product otoacoustic emissions. We describe this program of evidence-based ototoxicity monitoring protocols using a case example to give the reader an understanding of how this program would be applied, along with a plan for future work to accomplish the final stages of program development.
    The Journal of Rehabilitation Research and Development 04/2014; 51(1):81-100. DOI:10.1682/JRRD.2013.04.0092 · 1.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: http://www.rehab.research.va.gov/jour/2014/515/pdf/contents515.pdf
    The Journal of Rehabilitation Research and Development 11/2014; 51(5). DOI:10.1682/JRRD.2014.04.0093 · 1.43 Impact Factor